GlycoMimeticsGLYC
Market Cap: $10.7M
About: GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Employees: 35
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,434% more call options, than puts
Call options by funds: $675K | Put options by funds: $44K
17.74% less ownership
Funds ownership: 57.39% [Q1] → 39.65% (-17.74%) [Q2]
49% less funds holding
Funds holding: 69 [Q1] → 35 (-34) [Q2]
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
92% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 37
94% less capital invested
Capital invested by funds: $111M [Q1] → $7.2M (-$104M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for GLYC.